Greenphire Appoints Chief Commercial Officer
News Jul 12, 2012
Greenphire has announced the appointment of John M Blakeley to the role of Chief Commercial Officer.
Blakeley will lead Greenphire’s global marketing and sales strategy as the company continues to extend the adoption of its clinical payment technology platforms, the ClinCard System and the eClinicalGPS, to the pharmaceutical, medical device, and contract research markets.
Prior to joining Greenphire, Blakeley spent 10 years in senior management and executive roles at clinical service and medical device provider ERT, most recently serving as ERT’s Chief Commercial Officer.
“Greenphire is truly a rising star in our industry, unlike almost any young clinical technology company we’ve seen in the last decade,” said Blakeley.
Blakeley continued, “The team is motivated and savvy, and the technologies they’ve developed shift the global clinical payment paradigm on the same scale that EDC, IVR and ePRO have done for clinical data in years past. It’s a thrill for me, both professionally and personally, to continue to be at the cutting edge of technological innovation which will ultimately make drug development and medical discovery less expensive and more efficient.”
Greenphire CEO Sam Whitaker reciprocated Blakeley’s comment and shared his optimism with regards to the company’s future.
“John’s track record speaks for itself,” he said. “When John started at ERT it was still a relatively early-stage company, and the vision and leadership he exhibited in bringing clinical solutions to a global market is a model for any young company in our industry. John is an exemplary leader and an innovative thinker, and the Greenphire team is excited to work with him to further establish Greenphire as a pillar in the clinical research industry and the leader in clinical payment technologies.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE